| Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination BE Hast, D Goldfarb, KM Mulvaney, MA Hast, PF Siesser, F Yan, ... Cancer research 73 (7), 2199-2210, 2013 | 298 | 2013 |
| Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B‐cell lymphoma KA Cycon, K Mulvaney, LM Rimsza, D Persky, SP Murphy Immunology 140 (2), 259-272, 2013 | 80 | 2013 |
| Identification and characterization of MCM3 as a Kelch-like ECH-associated protein 1 (KEAP1) substrate KM Mulvaney, JP Matson, PF Siesser, TY Tamir, D Goldfarb, TM Jacobs, ... Journal of Biological Chemistry 291 (45), 23719-23733, 2016 | 75 | 2016 |
| Molecular basis for substrate recruitment to the PRMT5 methylosome KM Mulvaney, C Blomquist, N Acharya, R Li, MJ Ranaghan, M O’Keefe, ... Molecular cell 81 (17), 3481-3495. e7, 2021 | 48 | 2021 |
| Discovery of a first-in-class inhibitor of the PRMT5–substrate adaptor interaction DC McKinney, BJ McMillan, MJ Ranaghan, JA Moroco, M Brousseau, ... Journal of medicinal chemistry 64 (15), 11148-11168, 2021 | 31 | 2021 |
| Loss of SWI/SNF chromatin remodeling alters NRF2 signaling in non–small cell lung carcinoma S Song, V Nguyen, T Schrank, K Mulvaney, V Walter, D Wei, T Orvis, ... Molecular Cancer Research 18 (12), 1777-1788, 2020 | 28 | 2020 |
| Engineering a genetically encoded competitive inhibitor of the KEAP1–NRF2 interaction via structure-based design and phage display G Guntas, SM Lewis, KM Mulvaney, EW Cloer, A Tripathy, TR Lane, ... Protein Engineering, Design & Selection 29 (1), 1-9, 2016 | 27 | 2016 |
| A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue BM Bowman, SA Montgomery, TP Schrank, JM Simon, TS Ptacek, ... The Journal of pathology 252 (2), 125-137, 2020 | 19 | 2020 |
| Dissecting the Keap1/Nrf2 pathway through proteomics TY Tamir, KM Mulvaney, MB Major Current Opinion in Toxicology 1, 118-124, 2016 | 10 | 2016 |
| Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP M Bushway, KA Cycon, K Mulvaney, SP Murphy Immunogenetics 62, 109-116, 2010 | 10 | 2010 |
| Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP-Deleted Cancers KM Mulvaney Cancer Discovery 13 (11), 2310-2312, 2023 | | 2023 |
| PRMT5 substrate recruitment as a therapeutic target in CDKN2A/MTAP null cancers KM Mulvaney, B McMillan, C Blomquist, N Acharya, M Ranaghan, ... Cancer Research 82 (12_Supplement), 94-94, 2022 | | 2022 |
| Discovery of Covalently-bound, First-in-Class Allosteric Inhibitor of PRMT5 D McKinney, M Ranaghan, B McMillan, M Brousseau, M O’Keefe, ... European Journal of Cancer 138, S1, 2020 | | 2020 |
| Dissecting the Keap1/Nrf2 Pathway Through Proteomics MBM Tigist Tamir, Kathleen Mulvaney Current Opinion in Toxicology 1 (Dec 2016), 118-124, 2016 | | 2016 |
| Abstract LB-081: Elucidating the function of MCM3 ubiquitination by KEAP1: crosstalk between redox-sensing and cell cycle progression KM Mulvaney, J Matson, F Yan, D Goldfarb, J Cook, MB Major Cancer Research 75 (15_Supplement), LB-081-LB-081, 2015 | | 2015 |
| Proteomic dissection of KEAP1/NRF2 signaling to determine new pathway interactors in cancer KM Mulvaney The University of North Carolina at Chapel Hill, 2015 | | 2015 |
